Exploration of autoimmune disease target tissues reveals novel drug targets
Researchers suggest that identifying new treatments for autoimmune diseases requires studying the immune system AND target tissues together.
List view / Grid view
Researchers suggest that identifying new treatments for autoimmune diseases requires studying the immune system AND target tissues together.
A new analysis suggests SARS-CoV-2-specific antibodies remain relatively stable for eight months and Spike protein-specific memory B cells increase in number over time.
Discover how workflows are being accelerated to speed up the vaccine research and development process while maintaining safety and immunogenicity.
Immunology study shows that NF-kappa B-inducing kinase (NIK) is critical to T cell metabolism and the antitumour immune response.
Researchers have shown rhesus macaques and baboons develop strong signs of acute viral infection from SARS-CoV-2, making them ideal models.
By inhibiting the activity of microRNA-194 (miR-194), scientists prevented prostate cancer cells from developing treatment resistance in vitro.
Researchers have identified microbes that could affect the way a person metabolises glucose and lipids, leading to a potential treatment for type 2 diabetes.
A new study reveals that the healing process following a brain injury could initiate the growth of glioblastoma cancers.
A new study suggests that inflammation and blood vessel damage may be the primary causes of neurological symptoms in COVID-19 patients, instead of the virus infecting the brain.
Baidyanath Dash explains the two requirements for COVID-19 drug development: killing the virus and boosting immunity.
Anthony Finbow explains how applying microbiome-based evidence to disease modelling will enable researchers to devise more targeted treatments.
According to new research, because women have two copies of the ACE2 protein, they are less likely to suffer from severe COVID-19, unlike men who have one copy.
In this article Andrew Nyborg from Horizon Therapeutics discusses why researchers are taking a second look at gout and how they are modelling the condition, which is unique to humans.
17 December 2020 | By Living Systems Institute, University of Exeter
Watch our on-demand webinar where we explore new methods to improve data quality from high-throughput screens. You'll learn about solutions for common problems in drug-target discovery and our keynote speaker will also look at case studies where new approaches to screening have identified high-quality candidate drugs for proliferative diseases.
Researchers have shown that neutralising antibodies developed in COVID-19 patients were less potent if from those with severe or fatal disease.